Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Group 1 - The conference call is focused on the data update for Onvansertib, a drug developed by Cardiff Oncology [1] - The call is led by the Interim CEO, Mani Mohindru, along with key members of the Cardiff Oncology team including the Chief Medical Officer and Chief Scientific Officer [2] - The company will be making forward-looking statements regarding guidance, results, and timing of data readouts for Onvansertib clinical studies, which are subject to significant risks and uncertainties [3]